

Based on Form PTO-1449
(3/90)

ATTY. DOCKET NO.

674542-2003

SERIAL NO.

TECH CENTER 1800/2800
SEP 10 2002
1647

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

NIELSEN et al.

FILING DATE

February 19, 2002

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CSN	AA	US 5,874,469	2/23/99	Mamjar et al.			
	AB	US 4,608,251	8/26/86	Mia			
	AC	US 4,601,903	7/22/86	Frasch			
	AD	US 4,599,231	7/8/86	Milich et al.			
	AE	US 4,599,230	7/8/86	Milich et al.			
	AF	US 4,596,792	6/24/86	Vyas			
CSN	AG	US 4,578,770	3/25/86	Mitani			
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
CSN	AL	WO 95/05849	3/2/95	WIPO				
	AM	WO 94/03530	02/17/94	WIPO				
	AN	WO 00/20027	04/13/00	WIPO				
	AO	WO 95/07707	3/23/95	WIPO				
CSN	AP	WO 00/65058	11/2/00	WIPO				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CSN	AQ	Gregorius and Theisen, "In Situ Deprotection: A method for Covalent Immobilization of Peptides with well-defined orientation for use in solid phase immunoassays such as enzyme-linked immunosorbent assay" (2001) Analytical Biochemistry 299: 84-91
	AR	Barr and Mitchell, "ISCOMs (immunostimulating complexes): The first decade" Immunology and Cell Biology (1996) 74: 8-25.
	AS	Gosselin et al. "Enhanced Antigen Presentation using Human Fcγ Receptor (Monocyte/Macrophage)-specific immunogens" (1992) 149:3477-3481
	AT	Nilsson and Mosbach (1987) "Supports for Enzyme Immobilization" Methods in Enzymology 135: 67 .
	AU	Hermanson et al. "Immobilized affinity ligand techniques" (1992) 87.
CSN	AV	Morein et al. "Immunostimulating Complexes, Clinical Potential in Vaccine Development" Clin. Immunotherapy (1995) 3(6):460-475

EXAMINER

G. M. [Signature]

DATE CONSIDERED

2/25/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449
(3/90)

ATTY. DOCKET NO.

674542-2003

SERIAL NO.

10/099,101

APPLICANT

NIELSEN et al.

FILING DATE


February 19, 2002

GROUP

+645 1647

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
CD	AW	WO 00/05316	2/3/00	WIPO			
	AX	WO 98/23635	6/4/98	WIPO			
↓	AY	WO 93/15760	8/19/93	WIPO			
CD	AZ	WO 93/23076	11/25/93	WIPO			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CD	BA	Irving et al. "Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics" Current Opinion in Chemical Biology (2001) 5:314-324
	BB	Parker and Tomen, "Epitope Mapping by a Combination of Epitope Excision and MALDI-MS" Methods in Molecular Biology, 146: 184-201
	BC	Nelson et al. "Monoclonal antibodies" Molecular Pathology, Accepted for publication February 8, 2000
	BD	Nussinov and Wolfson, "Efficient Computational Algorithms for Docking and for generating and matching a library of functional epitopes II. Computer Vision-based techniques for the generation and utilization of functional epitopes.(1999) Combinatorial Chemistry and High Throughput Screening 2: 261-269.
	BE	Rothbard and Taylor, "A sequence pattern common to T-cell epitopes" 93-100
	BF	De Groot et al. "From genome to vaccine: in silico predictions, ex vivo verification" Vaccine 19 (2001) 4385-4395.
	BG	Rammensee et al. "MHC ligands and peptide motifs: first listing" Immunogenetics (1995) 41: 178-228.
	BH	Schirle et al. "Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach" Eur. J. Immunol. (2000) 30: 2216-2225
	BI	Southwood et al. "Several Common HLA-DR Types share largely overlapping peptide binding repertoires" The Journal of Immunology, 1998, 160: 3363-3373.
	BJ	Singagalia et al. "A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules" Nature Vol. 336 22/29 December 1988, 778-780
	BK	Chicz et al. "Specificity and Promiscuity among naturally processed peptides bound to HLA-DR Alleles" (1993) J. Exp. Med. 178: 27-79
	BL	Hammer et al. "Promiscuous and Allele-specific anchors in HLA-DR-Binding Peptides" (1993) Cell, vol. 197-203
	BM	Falk et al. "Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing and general rules" Immunogenetics (1994) 39: 230-242
	BN	Alexander et al. "Serum interleukin 5 concentrations in atopic and non-atopic patients with glucocorticoid-dependent chronic severe asthma" Thorax (1994) 49:1231-1233.
	BO	Dempsey et al. "C3d of complement as a molecular adjuvant: bridging innate and acquired immunity" (1996) Science 271: 348
↓	BP	Lou and Kohler, "Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide" Nature Biotechnology (1998) 16: 458-462
CD	BQ	Gregorius et al. "Hydrocoating: a new method for coupling biomolecules to solid phases" Journal of Immunological Methods (1995) 181: 65-73

EXAMINER

DATE CONSIDERED

2/25/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CONSIDERED, DO NOT PRINT (NO DATE)